Parkinson's Research Notes - Discovery Package
Inventory item: 8458 | SKU: 2039 | Line: Blueprints
Page: https://cri-one.com/12-parkinsons-research-notes-discovery.html
Owner and author: Christopher Gabriel Brown (CRI-ONE)
Record date: 8 October 2026
Approved public wording item: medical and regulatory wording follows D:/special/_inventory/descriptions-public/8458.md
1. The Record in Brief
Parkinson's Research Notes - Discovery Package is a research and discovery IP record by Christopher Gabriel Brown (CRI-ONE): an Alchemy Data V2 computational scan that returned 29 research-candidate compounds across 16 mechanism categories, delivered with its discovery data, discovery script, four formal patent figures and U.S. application text (Evidence 1, 5, 6, 7). Its earliest dated disclosure is Invent Depositions, ISBN 978-1-979767-89-7, first shipped 24 November 2017, where deposition #769 on printed page 181 records the brain chemical-balance principle behind the research (Evidence 9). Its USPTO anchor is U.S. Application No. 19/445,644, filed 12 January 2026, Confirmation No. [redacted], pending, joined by the pending umbrella applications 19/540,453 and 19/693,405 (Evidence 3, 4, 10, 11, 12). Its first public listing is dated 12 March 2026, and its current item page and card Buy button went live on 8 October 2026 (Evidence 13, 14, 15). Its text, drawings, code and data are marked "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (Evidence 2).
2. Proprietary - What Is Owned and How It Is Held
The source package holds 72 files in seven subfolders (folder count of 8 October 2026), in four families:
- Discovery data and code: the 29-record discovery JSON and six findings reports in three dated passes, V1, V2 and V3 (Evidence 5); the 609-line discovery script, its configuration, the raw Alchemy Data V2 output and the USPTO-compliant application text (Evidence 6).
- Drawings: FIG 1 to FIG 4 in SVG and PDF (Evidence 7), four editable SVG drawings and two 11 x 17 wall charts.
- Patent papers: the application text, a 20-claim summary, the filing-receipt record (Evidence 3), nine USPTO forms files including the N417 receipt, and two Office-response documents.
- Documentation: README, methodology, safety statement, LICENSE, MANIFEST.json, CITATION.cff, CHANGELOG and nine sales-pitch files.
A second copy of 58 files under D:/special/45-fda-rebuttles-and-adwork/ carries a byte-identical LICENSE.
Ownership. The LICENSE states that the Work is "the exclusive property of Christopher Gabriel Brown." He is the sole named inventor of 19/445,644 (Evidence 1, 3). No assignment is of record.
What a buyer receives. The LICENSE reads "NO LICENSE IS GRANTED." (Evidence 2). The item page states that "no license, express or implied, is conveyed by the sale of this research-notes package; the invention rights remain with the inventor." (Evidence 15). The purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." and must be accepted at checkout in a required field of each Payment Link (D:/special/crione-static/pages/terms/index.html; D:/special/crione-static/delivery-v2/deliver.py). The item page repeats that term beside its Buy button (Evidence 15).
Secrecy measures (18 U.S.C. 1839(3)). Full packages go only to paying buyers: the delivery program confirms each purchase with Stripe and e-mails the buyer a private download link valid for 7 days (D:/special/crione-static/delivery-v2/deliver.py; D:/special/crione-static/delivery-v2/config.json), and the item page states "Your files arrive by email after payment." (Evidence 15). The CRI-ONE Mutual NDA, version 2026-10-08, is published at https://cri-one.com/nda/ (D:/special/crione-static/pages/nda/index.html), and its full text comes with every delivery e-mail (D:/special/crione-static/delivery-v2/config.json). The public item page carries only the description; the JSON, script, raw output, reports and drawing files stay inside the delivered package.
3. First Art - The Earliest Dated Disclosure
| Date | Record | What it discloses | Source |
|---|---|---|---|
| 24 Nov 2017 | Invent Depositions, ISBN 978-1-979767-89-7, deposition #769, page 181 | The proper chemicals in the brain without poisoning other organs | Evidence 9; D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md |
| 2017 (entry mark) | 2017 catalog, deposition #133 | Diagnosing dopamine and other receptor-site changes in the central nervous system | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv; Evidence 8 |
| 2017 (entry mark) | 2017 catalog, deposition #486 | Computational predictive alchemy studies, the origin of Alchemy Data | entries-clean.csv; Evidence 8 |
| 12 Jan 2026 | U.S. Application No. 19/445,644 filed | 12 compound types in four independent claim families; 20 claims; 4 figures | Evidence 3, 4 |
| 12 Jan 2026 | Alchemy Data V2 discovery run | 29 candidates across 16 mechanism categories | Evidence 1, 5 |
| 12 Mar 2026 | Store listing "Open Research: Parkinsons Mechanism Analysis" | Public listing of the research line | Evidence 13 |
Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_A.json, confirmed in the master IP register, Evidence 8):
- #133, anchor 2017 catalog, entry marked copyright © 2017 chris g brown, register line 369: "mission 1 diagnose changes at dopa mine serotonin adrenaline and histamine receptor sites in the central nervous system by using a similar method to diabetic blood testing."
- #769, anchor printed book page 181, register line 1500: "chemical balance relation goal is the chance to achieve the proper chemicals in the brain or an organ to make it work better and function regulatory like while not poisoning the other organs"
- #486, anchor 2017 catalog, register line 1186: "computational predictive plasma sorting lapidary alchemy studies"
The master IP register (1,769 lines, Evidence 8) is the source of record; its copies in 50-pcie8-standard and 43-redaction-pen carry the same SHA-256.
Defensive-publication effect. Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 entries stand against every later filer on the subject matter they disclose, and the item page of 8 October 2026, which publishes the four claim families and the 29-compound ranking, stands against every later filer on that matter. A challenger must produce a dated record earlier than 24 November 2017 disclosing the same research line, or earlier than 12 January 2026 disclosing the same complexes. None is of record.
Prior Art Considered and Distinguished
The site provenance file keys six portfolio-level references to SKU 2039 (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json); each is written below with its title as recorded in D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json. The product's documented structure is amino-acid coordination chemistry and an elemental mechanism-overlap search (Evidence 1).
| Reference | Title (PRIOR_ART_REGISTER) | Distinction |
|---|---|---|
| US 4,775,876 | Photon recycling light emitting diode | LED photon recycling; a different field |
| US 2012/0305059 A1 | Photon recycling in an optoelectronic device | Optoelectronic photon recycling; a different field |
| US 2010/0183919 A1 | Quantum dot ultracapacitor and electron battery | Quantum-dot energy storage; a different field |
| US 6,175,719 B1 | Multi-Spot-Beam Satellite | Satellite payload; a different field |
| US 7,418,236 B2 | Extraterrestrial Communications Systems | Satellite-terrestrial communications; a different field |
| US 11,258,379 B2 | Quantum Noise Power Devices | Quantum energy harvesting; a different field |
The package's literature cross-references, led by Monti et al. 2019 (PMID 31048906) on N-acetyl-cysteine, document known biology. Independent Claims 1 to 4 are directed to zinc-halogen, boron/silicon, multi-metal and hybrid amino-acid coordination complexes, not to N-acetyl-cysteine, and the package's search of PubMed, Google Scholar and pharmaceutical databases returned zero published studies on any zinc-halogen amino-acid complex for any neurodegenerative disease (Evidence 1).
4. First to File - The USPTO Record
| U.S. Application | Filed | Status of record | What it covers for this product | Source |
|---|---|---|---|---|
| 19/445,644 | 12 Jan 2026 | Pending; reply with fees and extension recorded as filed 17 Sep 2026 | The package subject matter: 20 claims, 4 figures | Evidence 3, 4, 10 |
| 19/540,453 | 13 Feb 2026 | Pending; Filing Receipt mailed 27 Jul 2026 | Umbrella naming the disease-discovery systems (Projects 10 to 13) | Evidence 11 |
| 19/693,405 | 30 May 2026 | Pending; Filing Receipt mailed 25 Jun 2026 | Flagship umbrella; Project 12 is entry 12 of its as-filed catalog | Evidence 12; D:/manager/work/2 current_work_catalog.txt |
Every application is dated by its own effective filing date. 19/445,644 carries 12 January 2026, 01:28:59 ET, Patent Center No. 73928275 (Evidence 3); the N417 receipt delivered inside the package is byte-identical to the USPTO receipt on file (Evidence 4). The register records no benefit claim for 19/445,644 or 19/540,453, and the 19/693,405 Filing Receipt lists none; each application stands on its own date (D:/Rebuttals/_registers/USPTO_REGISTER.json). A challenger must produce an application with an effective filing date before 12 January 2026 claiming the same complexes. None is of record.
Marking line: Patent pending - U.S. Application Nos. 19/445,644, 19/540,453 and 19/693,405.
5. First to Market - The Dated Public Offering
| Date | Event | Where | Source |
|---|---|---|---|
| 12 Mar 2026 | Listing "Open Research: Parkinsons Mechanism Analysis" created | cri-one.com, old store | Evidence 13 |
| 19 Apr 2026 | Provenance ledger lists the listing as first posted | cri-one.com/store/ | D:/manager/first-to-market/first-to-market-LEDGER.csv |
| 31 Aug 2026 | Blueprint record SKU 2039 created | cri-one.com, old store | D:/manager/_store/export_catalog_product_20260831_201548.csv |
| 1 Sep 2026 | Record re-created; kept in the 7 Sep 2026 export | cri-one.com, old store | D:/manager/export_catalog_product_20260907_110415.csv |
| 4 Sep 2026 | Delivery file of record dated | Delivery copies | D:/special/crione-static/delivery-v2/product_deliverables.csv |
| 8 Oct 2026, 03:55 UTC | First new-site email campaign to US company prospects started | cri-one.com mail | D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json (site events); D:/special/_mailer/campaigns/new-site-2026-10/campaign.json |
| 8 Oct 2026 | Item page published | cri-one.com/inventory/item-8458/ | Evidence 15 |
| 8 Oct 2026, 05:06 UTC | Stripe card Payment Link (created 04:55:57Z) public as the Buy button | Item page | Evidence 14 |
6. Copyright
Notice: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (package LICENSE, Evidence 2). The item page carries "© 2026 Christopher Gabriel Brown. All rights reserved." and the patent-pending line for 19/445,644 (Evidence 15).
Works covered. Text (reports, methodology, application text), drawings (FIG 1 to FIG 4, wall charts), code (the discovery script) and data compilations (the discovery JSON and raw output). Copyright protects this expression; the compounds and methods are held by the patent filings and by confidentiality (17 U.S.C. 102(b)).
Registrations. The owner's written corpus is anchored by 20 registrations marked verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, effective 1 October 2010 to 15 March 2026, among them TX 8-396-625 (abstract, 2017), TX 8-657-127 (buy text, 2018) and TX 9-504-677 (estimated, 2025). The 2026 package is protected from fixation (17 U.S.C. 102(a)); registration is the gateway to suit (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).
Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core is human-authored: the numbered depositions written by Christopher Gabriel Brown, and his selection, arrangement and direction of this package, including shipping the V1, V2 and V3 passes side by side (Evidence 1).
Notice practice. The notice sits in the LICENSE, the sales-pitch product card and the item page; it defeats an innocent-infringer defense (17 U.S.C. 401(d)).
7. Firm Rebuttals
Challenge 1 - "None of this is original; the biology is already published."
Rebuttal. The package cites the known biology by PMID; the owner holds what the record dates as new. Depositions #133, #769 and #486 date the research line to 2017 (Evidence 8, 9); the 12 January 2026 filing dates the claimed complexes (Evidence 3), on which the package's literature search found zero published studies (Evidence 1). A challenger must produce an earlier dated record disclosing the same complexes. None is of record.
Challenge 2 - "Someone filed first."
Rebuttal. Under first-inventor-to-file, the challenger must produce an application with an effective filing date before 12 January 2026 claiming the same complexes. None is of record. Any later filer meets the dated 2017 and 2026 publications as prior art under 35 U.S.C. 102(a)(1).
Challenge 3 - "No patent has been granted, so there is nothing to respect."
Rebuttal. The owner holds U.S. Application No. 19/445,644, filed and pending, and two pending umbrella applications. "Patent pending" marking is correct while an application is pending (35 U.S.C. 292). The package is also held by copyright on fixation, by trade-secret measures of record, and by a dated record that stands as prior art against later filers.
Challenge 4 - "It was published, so it is free to use."
Rebuttal. Publication is disclosure. The LICENSE reads "NO LICENSE IS GRANTED." (Evidence 2); the item page states that no license, express or implied, is conveyed by sale (Evidence 15); the purchase term grants the use of that blueprint only. The first public listing of 12 March 2026 postdates the 12 January 2026 filing, so it is not prior art against 19/445,644 under 35 U.S.C. 102(a)(1). Copyright continues after publication.
Challenge 5 - "AI made it, so there is no copyright."
Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown, his Alchemy Data V2 database of elemental combinations, as the approved description records, and his selection, coordination and arrangement of this package (Evidence 1, 8, 9). The March 2023 Copyright Office guidance protects exactly that.
Challenge 6 - "The dates can be faked."
Rebuttal. The dates rest on third-party records. ISBN 978-1-979767-89-7 identifies the CreateSpace edition first shipped 24 November 2017 (D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md); Buy-Invent 2020 carries ISBN 979-8634479828 and Amazon ASIN B086PVSKFM (D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, books). Internet Archive first captures date crioner.com to 23 January 2010, cri-one.com to 28 January 2011 and buyinvent.com to 5 March 2014 (D:/manager/first-to-market/wayback_evidence.json). The USPTO assigned Confirmation No. [redacted] and mailed both umbrella Filing Receipts (Evidence 4, 11, 12); Stripe stamped the Payment Link 2026-10-08T04:55:57Z (Evidence 14). This record's files are fingerprinted by SHA-256 in D:/Rebuttals/_evidence/8458.sha256.
Challenge 7 - "The application title says 'Methods for Treating Parkinson's Disease', so this is a medical claim."
Rebuttal. This is a research and discovery IP record and makes no treatment claim. Patent claims define the scope of the right sought at the USPTO; they represent to no one that a compound works. The approved description states that the package is "not a medicine, not a supplement, not a treatment recommendation, and not medical advice" (Evidence 1, 15).
Challenge 8 - "A discovery score of 50.5 out of 100 and a probability of 0.010094 prove nothing."
Rebuttal. The owner's methodology defines the figures, and the record holds them exactly. The discovery score "reflects database coverage and mechanism overlap, not therapeutic probability", and the probability value "is a mathematical calculation from the Alchemy system, not a clinical success rate" (Evidence 1). The discovery JSON records the top signature C-H-O-N at discovery_score 50.5046961402217 and probability 0.010093922804433985 (Evidence 5), from a scan of "on the order of 24.4 million element combinations against approximately 257,500 catalogued synthesis methods" (Evidence 1).
Challenge 9 - "It is just an idea."
Rebuttal. The package is concrete work product: a 29-record discovery JSON, a 609-line discovery script with configuration and raw output, six findings reports in three dated passes, four formal patent figures in SVG and PDF, two wall charts, the application text, a 20-claim summary and the USPTO receipt and forms set (Section 2; Evidence 3 to 7).
8. Evidence Index
| # | File | SHA-256 (first 16 hex) | What it proves |
|---|---|---|---|
| 1 | D:/special/_inventory/descriptions-public/8458.md | af69e3faff15bd86 | Approved public wording, contents, figure definitions |
| 2 | D:/special/12-parkinsons-cure-discovery/LICENSE | 441e5d6f7a15bae3 | Copyright notice, exclusive property, no license granted |
| 3 | D:/special/12-parkinsons-cure-discovery/PATENT_FILING_RECEIPT.md | 57091509a67d3520 | 19/445,644 filing date, time and numbers |
| 4 | D:/USPTO Responses/Receipts/N417parkinsons.pdf | bb5b87bad4927f62 | USPTO receipt; identical copy in the package |
| 5 | D:/special/12-parkinsons-cure-discovery/findings/parkinsons_cure_discoveries.json | c517504e11b603bd | 29-record discovery data |
| 6 | D:/special/12-parkinsons-cure-discovery/_internal/run_parkinsons_discovery.py | b0679ae142f48c0a | 609-line discovery script |
| 7 | D:/special/12-parkinsons-cure-discovery/Drawings_19-445-644_Parkinsons/FIG_1_Chemical_Structures.pdf | ab8fac0a1dfb21df | Formal FIG 1 drawing |
| 8 | D:/special/82-alchemy-calc-two/1 light trigger.txt | 2dcb359de3f1b56d | Master IP register; depositions #133, #486, #769 |
| 9 | D:/manager/book-ocr-2017-invent-depositions/entries-index.csv | 9e72c4638df2ca6e | Deposition #769 on printed page 181 |
| 10 | D:/USPTO Responses/_MERGE_NOTE_2026-09-17.md | 7795fddecd6ca972 | 19/445,644 reply of 17 Sep 2026 |
| 11 | D:/USPTO Responses/EPSCAN/20160101_000000(14).PDF | aa5ee1477cc821c0 | 19/540,453 Filing Receipt |
| 12 | D:/USPTO Responses/EPSCAN/20160101_000000(35).PDF | b858723d9abb8e1e | 19/693,405 Filing Receipt |
| 13 | D:/manager/export_catalog_product_20260408_165843.csv | 1ec6bd9793cf5541 | Store listing created 12 Mar 2026 |
| 14 | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json | 96abb64653254b86 | Stripe Payment Link timestamp |
| 15 | D:/special/crione-static/site-inventory/inventory/item-8458/index.html | abde0c07bcc70b8c | Public item page, no-license statement, notice |
9. Notice Line
© 2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/445,644, 19/540,453 and 19/693,405.
cri-one.com/12-parkinsons-research-notes-discovery.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.Go to cart